Waller et al., 2010 - Google Patents
Osteopontin in cardiovascular disease: a potential therapeutic targetWaller et al., 2010
- Document ID
- 6899426598294711320
- Author
- Waller A
- Sanchez-Ross M
- Kaluski E
- Klapholz M
- Publication year
- Publication venue
- Cardiology in Review
External Links
Snippet
Osteopontin (OPN), also known as 44kDa bone phosphoprotein, sialoprotein I, secreted phosphoprotein I, 2ar, uropontin, and early T-lymphocyte activation-1 (Eta-1), is a multifunctional protein. OPN has been found to be expressed in various cell types and …
- 108010081689 Osteopontin 0 title abstract description 183
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Waller et al. | Osteopontin in cardiovascular disease: a potential therapeutic target | |
| Strand et al. | Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan‐4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure‐overloaded heart | |
| Rupert et al. | Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia | |
| Cocciolone et al. | Elastin, arterial mechanics, and cardiovascular disease | |
| Vaahtomeri et al. | Lymphangiogenesis guidance by paracrine and pericellular factors | |
| Wanga et al. | Aortic microcalcification is associated with elastin fragmentation in Marfan syndrome | |
| Schwartz et al. | The intima: soil for atherosclerosis and restenosis | |
| Okamoto et al. | Matricellular proteins: new molecular targets to prevent heart failure | |
| Doggrell et al. | Vascular chymase: pathophysiological role and therapeutic potential of inhibition | |
| Carino et al. | Abdominal aortic aneurysm: evolving controversies and uncertainties | |
| Midwood et al. | The role of tenascin-C in tissue injury and tumorigenesis | |
| Shimazaki et al. | Periostin is essential for cardiac healingafter acute myocardial infarction | |
| Fernández‐Alfonso et al. | Role of PVAT in coronary atherosclerosis and vein graft patency: friend or foe? | |
| Horimatsu et al. | The role of perivascular adipose tissue in non-atherosclerotic vascular disease | |
| Gan et al. | Role of semaphorin 7a signaling in transforming growth factor β1–induced lung fibrosis and scleroderma‐related interstitial lung disease | |
| Newby et al. | Fibrous cap formation or destruction—the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation | |
| Nataatmadja et al. | Overexpression of transforming growth factor-β is associated with increased hyaluronan content and impairment of repair in Marfan syndrome aortic aneurysm | |
| Golledge et al. | The role of tenascin C in cardiovascular disease | |
| Golledge et al. | Mouse models for abdominal aortic aneurysm | |
| George et al. | Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy | |
| Segers et al. | Protease-resistant stromal cell–derived factor-1 for the treatment of experimental peripheral artery disease | |
| Larrieu-Lahargue et al. | Netrin-4 induces lymphangiogenesis in vivo | |
| Shen et al. | Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model | |
| Girousse et al. | The release of adipose stromal cells from subcutaneous adipose tissue regulates ectopic intramuscular adipocyte deposition | |
| Sano et al. | Lymphangiogenesis and angiogenesis in abdominal aortic aneurysm |